retatrutide shot Demand for Unapproved Weight-Loss Drug Surges on Social Media Medscape | Retatrutide, Eli Lilly's

GLP-1 side effects: Whats normal, whats not, and when to get help

These trials are examining its efficacy and safety in individuals with obesity and type 2 diabetes

Continued metabolic improvement

Coverage gaps, steep out-of-pocket costs, and payer-imposed roadblocks stall progress before treatment even begins, while stigma, fragmented care, and shifting patient perceptions chip away at long-term adherence

Data in weight loss Most of the existing empirical data on weight loss with GLP-1 agonists come from studies of individuals who are overweight or obese, with or without type 2 diabetes, rather than from studies using these agents to counteract iatrogenic weight gain

doi: 10.2337/diabetes.49.6.896